Physician profile
Jana B Johnson
NPI 1295701092
$2,087,373.55
in general payments reported to CMS, 2019-2025
17 companies · $424K in 2025
The $424K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270K · 2020: $113K · 2021: $134K · 2022: $263K · 2023: $426K · 2024: $457K · 2025: $424K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.1M · Travel and Lodging: $180K · Consulting Fee: $19K · Food and Beverage: $14K · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,093,552.40 |
| Travel and Lodging | $180,260.38 |
| Consulting Fee | $18,675.00 |
| Food and Beverage | $14,166.82 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $436,272.19 | 2019-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $354,638.82 | 2019-2022 | |
| Ucb, INC. | $301,449.61 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $278,631.51 | 2019-2025 | Tremfya |
| Incyte Corporation | $236,546.42 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $147,922.80 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $101,396.66 | 2019-2022 | |
| Genzyme Corporation | $82,144.02 | 2019-2025 | |
| Dermavant Sciences, INC. | $69,586.08 | 2022-2024 | Vtama |
| Celgene Corporation | $64,934.65 | 2019 | |
| Pfizer INC. | $13,096.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $526.38 | 2019-2023 | |
| Abbvie INC. | $167.90 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.58 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $15.34 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $13.89 | 2020 | |
| Dusa Pharmaceuticals, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jana Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.